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Abstrac t  
Glycolytic Metabolism of Macrophages Differs by Spatial Location and Subset in 
Tuberculous Granulomas 
 
Victoria Ann Gould, MS 
 
University of Pittsburgh, 2020 
 
Abstract 
 
Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis (Mtb), triggers 
the formation of granulomas in the host. Granulomas are composed of many different types of host 
immune cells including T and B lymphocytes, macrophages, and neutrophils (PMN). The 
metabolic pathways used by immune cells in granulomas are important for cell function and 
glycolytic metabolic pathways in granulomas may be involved limiting or promoting disease. By 
understanding immunometabolism in TB granulomas, we can improve diagnosis and potentially 
create new therapeutics to combat TB disease. GLUT1 is a glucose transporter that transports 
glucose into the cell. To determine what cell subsets express GLUT1 in a granuloma, IHC was 
performed on lung granuloma-containing tissue sections from non-human primates (NHP) that 
were experimentally infected with Mtb. These slides were stained for macrophage markers 
including CD11c and CD163, and GLUT1, before being imaged by fluorescence microscopy. 
Image analysis was performed using ImageJ to determine the total pixel area and percent pixel 
area of each cell marker occupied in granuloma cross sections, as well as co-localization between 
the macrophage markers and GLUT1. To identify if there is a relationship between glucose uptake 
and mycobacterial antigens, we performed a glucose uptake assay and hypoxic experiments using 
2-NBDG on monocyte-derived macrophages that were stimulated with inactivated Mtb. Image 
analysis revealed co-localization of different cell markers and GLUT1. When looking at co-
localization of CD11c and CD163 with GLUT1, we found that CD11c+CD163- epithelioid 
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macrophages, the cells in granulomas that are most commonly infected with Mtb, expressed more 
GLUT1 than interstitial and alveolar macrophages. Moreover, we see evidence that macrophages 
increase their glucose (2-NBDG) uptake when stimulated with inactivated Mtb. Identifying 
immune cells that express GLUT1 and what triggers these immune cells to switch to glycolytic 
metabolism will help us further understand overall granuloma metabolism and cell differentiation 
after Mtb infection. In terms of public health, by better understanding the immunometabolism of 
granulomas, it will improve monitoring of disease progression or to aid in the treatment of Mtb 
infection to help reduce tuberculosis cases worldwide.  
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1.0 Introduction 
 Mycobacterium Tuberculosis and TB: Past and Present 
Mycobacterium tuberculosis (Mtb) belongs to a group of facultatively intracellular bacteria 
that infect and cause disease in humans (1). These bacteria infect a wide variety of animals 
including deer, livestock, and badgers (2) and cause granulomatous disease including tuberculosis 
(TB), the disease most commonly associated with Mtb infection. TB is a disease of historic 
significance and has accounted for a large amount of morbidity and mortality going back to 
antiquity (3). For example, evidence of spinal TB in ancient Egyptians was found in mummies as 
far back as 3500 BC (4). In the 17th century, TB, also known as consumption and was widely 
present in England (5). John Locke, a English philosopher, attributed 20% of all death in London 
were due to TB (5). TB is not just a disease of the past and it remains a pressing global health 
concern. It is estimated that a third of the world’s population is infected with Mtb, with 10 million 
cases of active TB in 2018 worldwide and more than 1.5 million deaths from TB (6). The largest 
number of TB cases occur in South-East Asia, Africa, and Western Pacific (7). Moreover, TB is 
one of the top causes of death among people who are co-infected with HIV (6, 8). 
 TB Presentation, Treatment, and Vaccination 
Individuals are often described as having latent or active TB based on their symptoms and 
clinical signs (9). Nearly a third of world is estimated to have latent TB, a state where individuals 
 2 
are asymptomatically infected with Mtb, or at least have anti-Mtb responses suggesting they have 
been exposed to bacterium (9). Importantly, individuals with latent TB cannot transmit the 
bacterium but can progress to active TB if they become immunosuppressed by cytokine-
suppressing drug treatments, HIV infection, or diabetes (10, 11). Individual that have active TB 
have symptomatic disease and can transmit the bacterium to suspectable people by coughing, 
sneezing, or spitting into the air (12). About 5-15% of persons infected with Mtb will develop 
active disease and can transmit the disease to another person (13). Symptoms of active disease 
include cough with sputum and possible blood, chest pains, fever, night sweats, and weight loss 
(14). Sputum from people with active disease may contain detectable Mtb (14).  
A common way to determine Mtb infection in latent TB infection is using TB skin test 
(TST) or a positive interferon-gamma release assay (IGRA) if vaccinated with BCG for TB (15). 
Unfortunately, neither test can distinguish previous infection, clearance, or risk of disease 
progression to active disease (15). Laboratory diagnosis of active TB infection can be completed 
in several ways, such as culture methods that could take weeks to complete or molecular testing 
techniques provide more rapid diagnoses of TB (16). Culture methods require sputum of an 
infected patient to be placed into a medium that will promote the growth of the bacterium (16). 
Sputum can also be stained with Ziehl-Neelsen, fluorescently with auramine or 
auramine/rhodamine, or using acid-fast staining to stain for Mtb (16). Once growth is detected, 
specie-specific fluorescently-labeled nucleic acid probes can be used to identify the species of the 
bacterium (16). By using this method, results of the sputum culture will take about 2 weeks (16). 
Nucleic acid amplification, on the other hand, provides more rapid diagnosis of Mtb, including a 
PCR based method that targets the TB-specific portion or the 16s ribosomal RNA gene with a 
colorimetric detection system (16). Although PCR based methods are faster, there is a higher false 
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positives as compared to culture methods (16). Culture methods are the gold standard for 
confirmation of Mtb infection and allow for drug susceptibility testing and genotyping (17). TB 
can also be diagnosed with PET/CT, a clinical instrument that measures positron emission from a 
radiolabeled probe. 18F-FDG (fluorine-18 fluorodeoxyglucose) is the PET probe most commonly 
used for TB diagnosis, and this radiolabeled glucose analog can be used to image lung 
inflammation (15). Although this method cannot identify the cause of the inflammation, 
tuberculous granulomas can be detected by PET/CT and changes in PET avidity can be used to 
identify progression from latent to active TB disease (15). 
Treatment of drug sensitive TB requires accurate and early diagnosis, drug resistant 
screenings, and six months of two phases of drug regimens through directly observed therapy 
(DOT) (18). The first phase is using a treatment of four drugs, isoniazid, rifampicin, pyrazinamide, 
and ethambutol (first-line drugs) for two months (18). The next phase is four months using 
isoniazid plus rifampicin, which is considered a short course chemotherapy (18). Unfortunately, 
there a cases of multidrug resistance (MDR-TB) and extensively drug-resistant (XDR-TB) that 
requires more extensive treatment (18). In the case of MDR-TB, treatment is administered for a 
total of 20-28 months using first-line anti-TB drugs, followed by a combination of 4 second-line 
anti-TB drugs (para-amino salicyclic acid, streptomycin, ethionamide, ofloxacin, capreomycin, 
kanamycin, amikacin, or cycloserine) (18). XDR-TB treatment requires the use of third-line anti-
TB drugs, such as clofazimine, linezolid, amoxicillin plus clavulanate, imipenem plus cilastatin, 
or clarithromycin (18).  
The only vaccine currently available for TB is based on an attenuated strain of M. bovis 
(19). This vaccine strain, referred to as M. bovis bacillus Calmette-Guérin (hereafter referred to as 
BCG) was developed by using a virulent bovine strain of tubercle bacillus cultured in bile, 
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glycerin, and potato medium that was then sub-cultured at 3 week intervals (19). Due to WWI, 
230 sub-cultures were then carried out and produced a tubercle bacillus that failed to produce 
progressive TB in several animal models (1919) and in human trials (1921) and was therefore 
introduced to the public in 1931 (19). Today, there are three different BCG vaccines strains in 
which the majority of the world’s population is supplied (19). BCG’s greatest protective benefits 
are centered on preventing certain presentations including severe disease presentations in children 
that have military TB and TB meningitis, but it does not prevent pulmonary TB (20). Moreover, 
BCG’s efficacy is highly variable across populations and effectiveness is reduced over time (21). 
Revaccination does not have protective benefits in adults and the initial BCG vaccination can 
confound PPD testing for Mtb infection (15, 22). IGRAs remain useful because BCG does not 
contain the RD1 genomic region encoding the Mtb proteins recognized by IGRAs  (15, 23). 
 Models of TB Research 
There are a wide range of animal models that are available to study Mtb infection. These 
models include zebra fish, mice, rabbits, cattle, and non-human primates (NHP) (24). Each model 
has pros and cons in terms of pathology, immunology, and genetics related to tuberculosis in 
humans (24). For example, mice have diverse genetic and immunologic backgrounds that allow 
researchers to control specific characteristic such as removing particular genes to determine its 
relationship to disease progression (24). On the other hand, mice are unable to form granulomas 
that are phenotypically similar to disease in humans (24). This theme can be seen in every animal 
model, where some models bring certain characteristics that other models do not. For this thesis, 
we used granulomas from cynomolgus macaques, a NHP model that is physiologically and 
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immunologically similar to humans (1, 25). NHP can exhibit a broad range of lesions (or 
granulomas) that are phenotypically and functionally similar to humans granulomas (24). 
Additionally, many regents that are used in human immunology can be used on NHP (24). As 
stated previously, PET/CT with 18F-FDG is commonly used to identify pulmonary inflammation 
in humans (15). PET/CT can also be used in NHPs to identify  inflammation caused by Mtb 
infection (26).  
 Mtb Infection Leads to Granuloma Formation 
Granuloma formation is the hallmark of TB disease (1, 25). Granulomas can form in any 
tissue that becomes infected with Mtb but because Mtb is transmitted via aerosol route and the 
lung is the primary site of infection, granulomas are most commonly found in lung tissue (1). Once 
inhaled, Mtb are phagocytosed by alveolar macrophages in the respiratory tract (27). Although 
macrophages are normally good at killing bacteria, Mtb are evolved to stop the phagosomal 
maturation and macrophages are their preferred host cell (28). Once inside a macrophage, Mtb 
replicate until they lyse the cell, and in the lungs, this recruits other phagocytes including 
interstitial macrophages and neutrophils that can be subsequently infected and serve as new host 
cells (1, 29). This process is repeated until antigen or bacteria-containing dendritic cells migrate 
to lymph nodes and prime adaptive immune response against Mtb and T cells are recruited to the 
site of infection (30). The early stages of granuloma formation are not well understood, but in 
cynomolgus macaques, a nonhuman primate where Mtb infection leads to human-like TB disease 
(31), necrotic granulomas that have lymphocyte cuffs, well-differentiated macrophage regions, 
and necrotic centers are already formed by four weeks post infection (32). This timeframe also 
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coincides with the ability to detect granulomas by PET-CT (26). There are many types of 
granulomas, including necrotic (caseous) granuloma, which is the most common lesion for active 
TB (32). Other types include nonnecrotic, cellular, fibrocalcific, and suppurative granulomas (32). 
Although necrotic (caseous) granulomas are seen more in active TB, it can be present in latent TB 
as well (33). 
 Granuloma Macrophages are Phenotypically and Functionally Diverse 
Macrophages are major constituents of the cells that make up a granuloma and are found 
throughout these lesions but are especially abundant in the macrophage region (32). Macrophages 
in this region undergo distinct morphological changes and are referred to as epithelioid 
macrophages (25). Macrophages in the different granuloma regions are phenotypically different 
and CD11c and CD163 expression can be used to differentiate alveolar macrophages, lymphocyte 
cuff, and epithelioid macrophages (32). Alveolar macrophages are strongly CD11c+CD163+, 
while CD11c+CD163- macrophages (epithelioid) are seen in the macrophage region and CD11c-
CD163+ macrophages (interstitial) are seen in the lymphocyte cuff (32).  
Macrophage functions are often differentiated by the metabolic pathways they use for 
arginine catabolism (34, 35). Both M1 and M2 macrophages utilize arginine but (25) M1 
macrophages catabolize arginine via inducible nitric oxide synthase (iNOS) to produce the 
antibacterial gas nitric oxide whereas M2 macrophages use arginase 1 (Arg-1) to generate 
polyamines (25, 35). In mice, these functional states are often categorized into two different 
functional states (M1 and M2 polarized macrophages) where M1 macrophages have pro-
inflammatory and microbicidal functions driven by Th1 T cell cytokines including TNFy and IFNg 
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and M2 macrophages have anti-inflammatory pro-healing functions driven by Th2 cytokines 
including IL-4 (34, 36). Granuloma macrophages also express these enzymes and while the 
differences between M1 and M2 macrophage are not as distinct in primates as in mice, granuloma 
macrophages exhibit distinct functional states (32). Moreover, iNOS and Arg-1 expression were 
region specific with iNOS more strongly expressed in the macrophage region than the lymphocyte 
cuff, while the iNOS:Arg-1 ratio of these regions suggesting the epithelioid macrophages are more 
M1-like than lymphocyte cuff macrophages (32). 
 M1 and M2 Macrophages Use Different Routes to Generate ATP 
Immune cells, such as macrophages, use different metabolic pathways including oxidative 
phosphorylation and glycolysis to generate ATP under different conditions (1, 25). Glycolysis 
generates 2 molecules of ATP and oxidative phosphorylation generates 36 ATP from 1 molecule 
of glucose (37). Oxidative phosphorylation ultimately produces more ATP than glycolysis, but 
glycolysis produces ATP faster and provides metabolic intermediates that are needed for cell 
growth and proliferation (1). More so, enhanced glycolysis enables immune cells to generate 
biosynthetic intermediates to carry out effector functions such as phagocytosis and inflammatory 
cytokine production in macrophages (37). 
M1 and M2 macrophages differ in immune-metabolic response in the presence of Mtb (25). 
M1 macrophage polarization is characterized by an up-regulation of genes consistent with the 
Warburg effect (25). The Warburg effect is a phenomenon where cells switch their metabolic 
profile to utilize glycolysis to generate ATP even in the presence of oxygen, also referred to as 
aerobic glycolysis (25, 38). After stimulation with LPS or TLR ligation, M1 macrophages increase 
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hypoxia-inducible factor 1- (HIF1), expression associated with the Warburg effect (25, 39, 40). 
Overexpression of HIF1 will suppress mitochondrial oxidative phosphorylation (41, 42). Unlike 
M1 macrophages, M2 macrophages upregulates Arg-1, signal transducer and activator of 
transcription 6 (STAT6), and GATA binding protein 3 (GATA3) in order to produce anti-
inflammatory cytokine IL-10 (25). M2 macrophages have an intact TCA cycle to allow for the 
generation of ATP through oxidative phosphorylation and concomitantly display increased 
glycolysis as a carbon source (43, 44). Enhanced utilization of glycolysis occurs in other immune 
cells including dendritic cells (DCs), natural killer cells (NK), and T cells where it is important for 
rapid replication and high levels of activity including cytokine expression (37). Glycolysis is also 
important for tumor cells and enables them to survive and replicate rapidly in normoxic and 
hypoxic environments (38). 
The first step in glycolysis is transportation of glucose across the plasma membrane (45). 
Transport of glucose across the cell membrane is mediated by facilitative glucose transporter 
proteins (GLUTs), and there have been fourteen GLUTs identified so far (45). Each GLUT differs 
in their tissue distribution and affinity for glucose, but GLUT1 is expressed broadly throughout 
the body and heavily studied in cancer because it is elevated expression in almost all human 
cancers (45). GLUT1 is a well characterized glucose transporter expressed by leukocytes that has 
been used as an indicator of immune cell glycolysis metabolism (37). GLUT1 contains 492 
residues, containing N and C domains that take in substrate, such as glucose, into the cell (46). 
Substrate binding on the C domain induces the closure of the N and C domains on the extracellular 
side (46). As affinity for the intracellular side increases after substrate binding on the extracellular 
side, this causes GLUT1 to change to an open-conformation structure and allow substrate 
dissociation (46).  
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The metabolic interactions between immune cells in granulomas are not fully understood 
but may improve therapies that reduce the duration of TB treatment. This approach is currently 
being investigated for cancer, where targeting glycolysis is being explored as a tool for cancer 
treatment, either as an approach that directly targets tumor cells or enhances the activity of 
chemotherapeutic agents (47). Before this approach can be considered in TB, several aspects of 
granuloma biology need to be investigated to assess its feasibility. Moreover, PET-CT using 2-
fluoro-2-deoxy-D-glucose (18F-FDG), a glucose analog, has become an increasingly important tool 
for diagnosing TB (48). 18F-FDG accumulates in cells through glucose transporters (GLUT) and 
can be visualized by PET (49). Uncovering the drivers of glucose uptake, as visualized by 18F-
FDG PET, can be translated into meaningful insight into cellular changes in granulomas. In 
addition to 18F-FDG, studies have shown that 2-NBDG, a fluorescent analog of D-glucose, can 
also be used to as a probe for monitoring glucose uptake in malignant tumor cells (50). 
For my thesis, we used GLUT1 expression as a proxy for glycolytic metabolism in 
granulomas. Moreover, we used 2-NBDG in experiments with monocyte-derived macrophages to 
identify the relationship between Mtb antigens and macrophage glucose uptake, thus offering 
mechanistic insights into granuloma biology. The hypothesis addressed here is that macrophages 
from lung granulomas in regions of hypoxia or after exposure to Mtb antigens will express more 
GLUT1 as compared to regions of normoxic conditions or lower Mtb exposure. Thus, the specific 
aims are to (1) identify which cell types in granulomas use glycolysis as their energy source; and 
(2) identify potential drivers of glycolysis in granuloma macrophages. Figure 1 shows the 
workflow we used to test my hypotheses. I expect that a deeper understanding of 
immunometabolism in granulomas may lead to better diagnostics and therapeutics for this 
globally-significant disease. 
 10 
 
 
Figure 1. Workflow of Thesis Project 
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2.0 Methods and Materials 
We used GLUT1 expression as a proxy for glycolysis in granulomas. We hypothesized that 
macrophages may express significant levels of GLUT1 because previous work has shown that the 
macrophage region can be hypoxic (51) and these cells may need to use glycolysis to survive in 
this environment. To identify where GLUT1 is expressed and if granuloma macrophages use 
glycolysis as their energy source, slides with lung granulomas from Mtb-infected NHPs were 
obtained for immunohistochemistry (IHC). IHC allows for the staining of specific cell markers for 
different macrophage subsets and GLUT1. Then, these granulomas were imaged with a Nikon 
e1000 microscope to visualize GLUT1 expression and macrophages subsets. IHC is limited by the 
number of colors that can be visualized by our microscope, the different antibody host species that 
can be combined in one cocktail, and the different staining patterns of the cells can present a 
problem with analysis. In order to determine if other cells (T cells, B cells, neutrophils, and CD3-
CD20- lymphocyte-sized cells) express GLUT1 in granulomas, we stained single cell suspensions 
from NHP granulomas and measured their GLUT1 expression by flow cytometry.  
 To address my second aim of identifying potential drivers of glycolysis in granulomas, we 
used a glucose uptake assay using 2-NBDG, a fluorescent glucose analog where we stimulated 
monocyte-derived macrophages with gamma-radiated Mtb (yMtb). We also performed these 
experiments under hypoxic conditions to determine if these macrophages take up 2-NBDG in an 
environment with limited oxygen. We also measured if stimulation with yMtb changed 2-NBDG 
uptake.  
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 GLUT1 Expression in Macrophage Subsets in Lung Granulomas 
In order to conduct studies for my first specific aim (determining which cell subsets express 
GLUT1 within a granuloma), 23 slides with NHP lung granulomas were obtained. From these 
slides, we identified 33 granulomas from nine NHP (Table 1). We stain these slides by IHC using 
antibodies specific for cell markers including the macrophage markers CD11c and CD163, and 
glucose transporter GLUT1. We imaged these slides with a Nikon e1000 microscope to visualize 
macrophage and GLUT1 localization. We then used ImageJ to determine the total area (pixels) 
and percent area (pixels) each macrophage marker and GLUT1 staining.  
 
Table 1. Slides of Lung Tissue Granuloma Stained with GLUT1 CD11c CD163 
NHP # Sample 
# 
Tissue 
Type 
Granuloma Type ROI Area 
(pixels) 
M3609 12A1 LLL 
Medial/LLL 
cluster 
Coalescing caseous 51,526,122 
M3609 12A2 LLL 
Medial/LLL 
cluster 
Coalescing caseous 27,678,810 
M3609 12A3 LLL 
Medial/LLL 
cluster 
Coalescing caseous 50,753,910 
M6409 8 RLL 
Cluster 
B/RLL 
GR4 
Coalescing caseous 14,662,496 
M6410 6A RUL granl Interstitial 
scar/mineralization 
17,751,200 
M6410 6B RUL granl Interstitial 
scar/mineralization 
17,034,368 
M6410 21 RLL granl 
7B 
Necrotizing 12,462,606 
M6810 4 RUL GR 1 Necrotizing caseous 17,717,380 
M6810 21 RLL GR 6 Coalescing necrotizing 
(caseous) 
22,115,904 
M6810 24 RLL GR 9 Necrotizing caseous 19,657,524 
M7110 8 RLL GR 1 Coalescing necrotizing 
(fibrinoid) alveoltis 
8,341,952 
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M7110 10 RLL 3 GR Necrotizing with 
fibrinoid (early caseous) 
34,178,364 
M11208 26 RLL GR 6 Caseous 
(mineralization/fibrosis) 
44,720,068 
M12603 9A Lung GR Unspecified 15,785,324 
M12603 9B Lung GR Unspecified 52,718,262 
M18314 40A1 RML 10 
area 
Coalescing necrotizing 
(caseous) 
9,872,118 
M18314 40A2 RML 10 
area 
Coalescing necrotizing 
(caseous) 
12,520,848 
M18314 40A3 RML 10 
area 
Coalescing necrotizing 
(caseous) 
7,262,667 
M18314 40B1 RML 10 
area 
Coalescing necrotizing 
(caseous) 
22,354,392 
M18314 40B2 RML 10 
area 
Coalescing necrotizing 
(caseous) 
25,489,984 
M18314 40B3 RML 10 
area 
Coalescing necrotizing 
(caseous) 
12,527,352 
M18314 40C1 RML 10 
area 
Coalescing necrotizing 
(caseous) 
12,988,032 
M18314 40C2 RML 10 
area 
Coalescing necrotizing 
(caseous) 
10,270,916 
M18314 48A Access 
with granl 
Necrotizing and non-
necrotizing with 
possible fibrous 
7,763,080 
M18314 48B Access 
with granl 
Necrotizing and non-
necrotizing with 
possible fibrous 
34,872,848 
M18314 48C1 Access 
with granl 
Necrotizing and non-
necrotizing with 
possible fibrous 
10,439,048 
M18314 48C2 Access 
with granl 
Necrotizing and non-
necrotizing with 
possible fibrous 
12,551,070 
M18314 48C3 Access 
with granl 
Necrotizing and non-
necrotizing with 
possible fibrous 
4,208,268 
M21310 8 LLL 
cluster 8 
GR 
Coalescing 
necrotizing with TB 
pneumonia 
117,079,044 
M21310 23 Access 
granl 5 
Coalescence non-
necrotizing with 
fibrous 
8,864,456 
M21310 29 LLL granl 
4 
Necrotizing (caseous) 
and non-necrotizing 
18,059,424 
M21310 44 LUL granl 
1 
Fibrous necrotizing 
(caseous) and non-
necrotizing 
37,942,288 
Table 1 Continued 
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 Immunohistochemistry  
Antigen retrieval was performed as previously indicated (32, 52). The slides were 
deparaffinized by incubating them twice in xylene and then twice in 95% ethanol for five minutes 
each. The slides were then placed into antigen retrieval buffer and placed into a pressure cooker. 
After the pressure cooker ran its cycle, about 45 minutes, the slides were rinsed with PBS. Each 
slide contained two serial sections of tissue. One section was designated to be stained with 
antibodies against the markers of interest and the other served as a no-primary control for 
nonspecific binding. Both sections were blocked with 2% BSA-PBS for 30 minutes. The primary 
cocktail included antibodies against GLUT1, CD11c, and CD163. CD11c and CD163 are 
macrophage markers and can be used in different combinations to identify different macrophage 
where CD11c+CD163- cells are epithelioid macrophages, CD11c-CD163+ cells are interstitial 
macrophages, and CD11c+CD163+ cells are alveolar macrophages (32). The GLUT1 (polyclonal, 
dilution 1:30; Thermo Fisher Scientific), CD11c (clone 5D11, dilution 1:30; Leica Microsystems, 
Buffalo Grove, IL), and the CD163 (clone 10D6, dilution 1:50; Lab Vision).  After 30 minutes, 
the blocking buffer was removed, and the primary antibody cocktail was added to the tissue section 
designated for antibody staining and blocking buffer was added to the no-primary control tissue 
section and incubated for one hour. During this time, a cocktail of fluorophore-conjugated 
secondary antibodies specific to the primary antibody was made. The secondary antibodies for 
GLUT1, CD11c, and CD163 were AlexaFluora (AF) 594 anti-rabbit IgG, AF647 anti-mouse 
IgG2a, and AF488 anti-mouse IgG1, respectively. Once the one-hour incubation for the primary 
stains was complete, the slides were washed three times in 1X phosphate buffered saline (PBS), 
three times. Mounting media with DAPI, which stains nucleated cells, was used to adhere a 
coverslip to the slides.   
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 Microscopy 
Fluorescent microcopy was performed on a Nikon e1000 epifluorescence microscope 
operated by the Nikon NIS Elements software. Fluorescent microscopy uses excitation light that 
lets through radiation with a certain wavelength that is specific to the fluorophore that is attached 
to the sample of interest (53). This causes the electrons associated with the sample to be excited to 
a higher energy level and then relaxed to a lower level and emit light (53). Through different filters 
within the microscope, it is able to separate out much brighter excitation light from the lower 
energy emitted light to be viewed by the human eye (53). By using this microscopy technique, we 
could visualize GLUT1 expression and identify which macrophage subsets express GLUT1 within 
a lung granuloma. The microscope we used can image four channels including the wavelengths 
that excite DAPI (visualized as white), AF488 (green), AF594 (red), and AF647 (far-red; 
pseudocolored blue). To make our image analysis quantitative, the camera region of interest used 
for image acquisition, and camera exposure settings were consistent among all slides. All images 
were taken a with a 20x magnification with a non-oil immersion Nikon Plan APO lens.  
The image lookup tables (LUTs) were adjusted according to the no-stain control to 
minimize the autofluorescence and background for each fluorophore and the same set of LUTS 
was applied to all the images within a set. Each animal’s tissue has a different autofluorescence 
and background profile and the LUT table for each animal was adjusted independently. Images 
were acquired as four channel ND2 files and then converted into two TIFF files, one with only the 
DAPI channel, and the other with only the RBG (red-TRITC, pseudocolored blue-Cy5, and green-
FITC) channels. Some pieces of tissue were too large to be imaged in a single stitched field and 
needed to be imaged with several overlapping fields to get the whole tissue section of interest. 
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These photos were exported as TIFF files and merged together using Adobe Photoshop’s 
Photomerge feature and  analyzed with ImageJ.  
 Image Analysis with ImageJ 
Beth Junecko made a macro for ImageJ that allowed us to determine the total area and 
percent area in pixels of each marker of interest (Appendix 1). First, the macro requires the TIFF 
DAPI image to create a region of interest (ROI). By selecting an ROI, we were able to isolate 
specific granulomas within the image and remove any adjacent lung or tissue that is not involved 
in the granuloma. After the ROI is created, the macro requires the TIFF RBG image and applied 
the ROI to that image. From here, the macro splits the TIFF RBG image individual images for 
each channel (red (TRITC), blue, and green). The macro then goes through each channel and 
allows the user to adjust the threshold. By adjusting the threshold up or down, the user determines 
which pixel are foreground and background by choosing a value cutoff. Every pixel less than that 
value cutoff is considered in the foreground and every pixel more than that value is considered the 
background. For example, if the threshold is adjusted to 0, then no pixel is accounted for and if the 
threshold is adjusted to the max (255), then all pixels are accounted for within the image for that 
specific channel. But adjusting the threshold between 0 and 255, the user determines which pixels 
within that image are actually positive for that channel. Once the threshold is determined by the 
user, the macro will repeat this process for each channel and DAPI. Once the thresholds are 
determined for each channel and DAPI, the macro can then determine the total pixel area and 
percent pixel area for each channel and any co-localization of multiple channels together. For our 
macrophage markers, we looked at the overall expression of GLUT1, CD11c, and CD163 within 
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each granuloma. We also determine which macrophages expressed GLUT1 and CD11c only 
(epitheliolid), GLUT1 and CD163 only (interstitial), and GLUT1, CD11c and CD163 (alveolar) 
together. This allows us to determine which subsets of macrophages that were and were not 
expressing GLUT1. Additionally, we can see that there are cells that were not positive for our 
macrophage markers but expressed GLUT1.  
Each slide that was stained and analyzed to determine if there were multiple granulomas 
per slide (Table 1). In some cases, an individual block may contain multiple pieces of tissue and 
we have given letters to designate each tissue in these instances. Tissues with multiple granulomas 
were given a number along with the letter, for example, M18314 (40) had several pieces of tissue 
labeled as 40A, 40B, and 40C and these pieces contained several granulomas labeled as 40A1, 
40A2, 40A3, and so on. Lack of a letter and number designates that slide had one piece of tissue 
with one granuloma within that tissue.  
The type of granulomas we examined and size (number of pixels in each image) for each 
granuloma are indicated in Table 1. Granulomas come in several different phenotypes including 
fibrotic and mineralized granulomas and non-granulomatous lung contains structures that strongly 
express GLUT1 including ciliated epithelium. We focused on necrotic and non-necrotic 
granulomas because these granulomas are most similar to each other in terms of their cell types 
(and because the mineralized and fibrotic granulomas in our sample set were often damaged during 
sectioning) we selected ROIs that excluded fibrotic and mineralized granulomas, ciliated epithelia, 
and red blood cells (which also express significant amounts of GLUT1) for our analysis.  
The total area and percent area of pixels was determined for each color combination where 
each combination represents a cell population and GLUT1 expression state. Additionally, the 
number of cells within the granuloma by using DAPI was used to get a count for the number of 
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cells within each granuloma, since it stains the nucleus of each cell. Although we tried to quantify 
the number of macrophages per section, the morphology of these cells and the way they cluster 
together prevented us from quantifying them as individual cells and we used pixel areas occupied 
by the macrophage markers instead. 
 Flow Cytometric Analysis of GLUT1 Expression 
We applied a similar approach to assess GLUT1 expression by neutrophils and T cells by 
staining for calprotectin, a protein that is abundant in the cytoplasm of neutrophils, and CD3, 
respectively. While our staining worked, we found that the different staining patterns (cytoplasmic 
for neutrophils and cell surface for T cell) for the cell types and low signal:background ratio for 
the T cells limited our confidence in these results. To address this question, we stained cells from 
NHP granulomas and assessed them by flow cytometry. This work was performed under BSL3 
conditions by Josh Mattila and Beth Junecko and I contributed to data analysis. We obtained 
granulomas from three NHP that were included as untreated controls (n=3) in an ongoing study 
(23 total granulomas) (Table 2).  
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Table 2. Homogenized lung granulomas from NHP used in flow cytometry analysis of GLUT1 expression in T 
cells, B cells, and myeloid cells 
NHP # Granuloma # and Tissue Type 
22018:  
 
A- RLL 1 
B- LLL 7 
C- LLL 9 
D- LLL 4 
E- LLL 5 
F- RLL 3 
G- RLL 10 
H- RLL 11 
I- RLL 2 
 
23318:  
 
A- LLLgr3 
B - LLLgr1 
C - LLLgr2 
D - RLLgr4 
E - RLLgr3 
F - RLLgr2 
G- RLLgr1 
 
23818:  
 
A - LLL 1 
B - RLL 1 
C - RLL 3 
D - RLL 4 
E - RLL 2 
F - RLL 6     
G - LLL 4 
 
 
 
These granulomas were homogenized with Miltenyi gentleMACS tissue dissociators using 
the enzymes included in the human tumor dissociation kit. The single cell suspensions were stained 
with fluorochrome-conjugated antibodies against CD3 (T cells), CD20 (B cells), and the myeloid 
markers CD11b, CD11c, CD14, CD206, and GLUT1. After 20 minutes of incubation at room 
temperature, the cells were washed and fixed, transferred out of the BSL3 and intracellularly 
stained for calprotectin using the BD Cytofix/Cytoperm kit. Stained cells were run by Josh Mattila 
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on the BD LSRFortessa flow cytometer maintained by the Department of Infectious Diseases and 
Microbiology. Analysis was done with FlowJo using anticipated antigen expression profiles for 
each cell population under the gating strategy. For the purpose of the thesis, only animals that were 
left untreated (n=3) were used to analyze GLUT1 expression in T cells, B cells, and myeloid cells.  
  Experiments with 2-NBDG 
We used a fluorescent glucose analog, 2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino]-2-deoxyglucose) (Appendix 2), and Mtb-stimulated monocyte derived macrophages as 
a model for granuloma macrophages to determine if bacterial antigens can induce glucose uptake 
in granulomas. We also performed these experiments under hypoxic conditions in a desiccator 
where the oxygen had been removed by burning a candle to determine if hypoxia also contributed 
to glucose uptake.  
 Glucose Uptake Assay 
Monocytes were isolated from Percoll gradient-isolated PBMCs with Miltenyi anti-human 
CD14 magnetic beads and cultured in macrophage media made up of RPMI and 10% FBS (R10) 
in 12-well plates for 7-10 days. Then the cells were lifted off and reseeded onto 12-well chamber 
slides (about 50,000 cells/well) from four different NHPs (M22618, M13618, M21718, and 
M22118). To prepare the 2-NBDG from packaging, 5mg of the 2-NBDG was dissolved in 500uL 
of 100% ETOH (10mg/mL). A 1:4 mixture of 2-NBDG:PBS was made and 10 microliters of this 
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mixture was added to each well with no gamma-radiated Mtb (yMtb) and 2-NBDG only, as shown 
in Table 3. With the remainder of the 2-NBDG:PBS mixture, 5 microliters of yMtb was added. 
The wells that were designated to receive stimulation of yMtb, received 11 microliters of the yMtb-
2-NBDG:PBS mixture. At each timepoint, 100 microliters of the media from each duplicate well 
was removed and 200 microliters of 2% PFA was added to stop the reaction. Once all time points 
were completed, all media was removed, and the wells were washed with 1xPBS twice. The 
chamber was removed from the slide and Prolong Gold mounting media with DAPI was used to 
adhere a coverslip to the slide. For cells on slides, images were acquired of each well with a Nikon 
e1000 microscope and analyzed with a CellProfiler pipeline created by Josh Mattila to quantify 
macrophage 2-NBDG uptake by Mtb stimulated or unstimulated macrophages at different time-
points.  
 
Table 3. Conditions of Monocyte-Derived Macrophages in a 12-well Chamber Slide used in the Glucose 
Uptake Assay with 2-NBDG 
0 Hour 10 Minutes 30 Minutes 1 Hour 3 Hours Overnight 
yMtb- 
2-NBDG- 
yMtb+ 
2-NBDG+ 
yMtb+ 
2-NBDG+ 
yMtb+ 
2-NBDG+ 
yMtb+ 
2-NBDG+ 
yMtb+ 
2-NBDG+ 
yMtb- 
2-NBDG+ 
yMtb- 
2-NBDG+ 
yMtb- 
2-NBDG+ 
yMtb- 
2-NBDG+ 
yMtb- 
2-NBDG+ 
yMtb- 
2-NBDG+ 
 Hypoxia Experiments  
To determine if hypoxia could be a driver of glycolysis in immune cells, we performed a 
pilot experiment using monocyte derived macrophages from one Mtb-infected NHP (M32419) 
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where the cells were incubated in FACs tubes instead of on slides. These tubes either received no 
stimulation, 2-NBDG, yMtb, or 2-NBDG with gamma-radiated Mtb and were held in either an 
oxygenated “normal” environment or an oxygen-lacking hypoxic environment created in a 
desiccator where a candle had been burned. Cells in oxygenated conditions were put in a 37°C 
incubator. After 1 hour and 3 hours, the cells were stained for CD3, CD11b and a live/dead 
indicator stain. These cells were then washed with PBS and fixed using 2% PFA. These cells were 
then assayed by flow cytometry and analyzed using FlowJo to determine the frequency of cells 
that are positive for the cell markers and 2-NBDG.  
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3.0 Results 
 GLUT1 Expression in Different Cell Populations  in Lung Granulomas 
We used 23 slides from several different non-human primates (NHP) that were infected 
with Mtb and identified 33 granulomas in these tissues for analysis. We used 
immunohistochemistry (IHC) to stain the slides with antibodies against macrophages and GLUT1 
and then we used microscopy to image these sections. Our stains include GLUT1, CD11c, and 
CD163. GLUT1 is stains for glucose transporter 1, CD11c and CD163 are both markers for 
macrophages (Figure 2).  
 
Figure 2. Macrophage subsets in granulomas express GLUT1 
Red is GLUT1, blue is CD11c, and green is CD163. 
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Using ImageJ, we determined the total pixel area and percent pixel area of each stain in 
each granuloma to analyze GLUT1 expression by epithelioid, interstitial, and alveolar 
macrophages (Figure 3).  
 
 
Figure 3. Illustration of how each cell marker was analyzed individually and in colocalization with other cell 
makers to determine GLUT1 expression of macrophages in lung tissue granulomas 
 
 GLUT1 Expression in Macrophage Subsets 
To determine if there was a difference between GLUT1- and GLUT1+ macrophages for 
each subset, we performed a pairwise comparisons between subsets and used the Wilcoxon test 
which is a non-parametric test for paired groups to determine if these results were statistically 
significant. Based on this approach we found that for each macrophage subset, there was 
significantly more area occupied by GLUT1+ macrophages than area occupied by GLUT1- 
macrophages in granulomas (Figure 4).  
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Figure 4. GLUT1+ macrophages occupy more area than GLUT1- macrophages in granulomas 
Comparisons of the total pixel area of GLUT1+ to GLUT1- epithelioid, interstitial, and alveolar macrophage 
subsets. 
 
The granulomas we imaged were of substantially different size profiles and to normalize 
the differences in size with respect to the granuloma area occupied by each macrophage subset, 
we also did pairwise comparisons (Wilcoxon test) testing the percent of the granuloma occupied 
by a macrophage subset (Figure 5). Similar to our previous result based on the area occupied by 
each macrophage subset, we found a significantly higher proportion of the granuloma area was 
occupied by GLUT1+ macrophages than GLUT1-  macrophages. 
 
 
Figure 5. GLUT1+ macrophages occupy a higher proportion of the granuloma’s area than GLUT1- 
macrophages 
Comparisons of the percent pixel area of GLUT1+ to GLUT1- epithelioid, interstitial, and alveolar macrophage 
subsets. 
 
We then wanted to find out how much epithelioid, interstitial, and alveolar macrophages 
contributed to the overall GLUT1 expression in lung granulomas. Using a non-parametric one-
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way ANOVA (Friedman test) to allow multiple comparisons, we compared the total pixel area of 
the overall GLUT1 expression (total GLUT1+ pixels/ROI) in each granuloma to the GLUT1+ 
epithelioid, interstitial, and alveolar macrophage subsets. We found that there was a significant 
difference for each macrophage subset and the overall GLUT1 expression (Figure 6). We then 
summed the GLUT1 expression of all macrophage subsets (epithelioid, interstitial, and alveolar) 
and compared that to the overall GLUT1 expression. We found a significant difference in the total 
pixel area between the summed GLUT1 expression of macrophage subsets and the overall GLUT1 
expression in lung granulomas (Figure 6).  
 
 
Figure 6. Macrophage GLUT1 contributes to, but is not the only source, of granuloma GLUT1 expression 
Comparison of the total pixel area of the GLUT1 expression in each macrophage subset and the sum of all GLUT1+ 
macrophages to the overall GLUT1 expression in lung granulomas. 
 
To normalize the difference in size of each granuloma, we also made these comparisons 
using the Friedman test but with the percent pixel area and found the same trend (Figure 7) 
indicating that in macrophages are not the only cell population that contributes to GLUT1 
expression in lung granulomas.  
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Figure 7. Macrophage GLUT1, when normalized for granuloma area, partially contributes to overall 
granuloma GLUT1 expression 
Comparison of the percent pixel area of the GLUT1 expression in each macrophage subset and the sum of all 
GLUT1+ macrophages to the overall GLUT1 expression in lung granulomas. 
 
Since the above analysis treats each granuloma from each NHP individually, we decided 
to look at the data differently by finding the mean total pixel area and percent pixel area among all 
granulomas for each NHP. Although each granuloma is independent from other granulomas within 
a host, the response by the host can differ among different hosts. By grouping all granulomas for 
each NHP and determining the mean, it allows our results to be reproducible and more general 
among NHP. Figure 8 compares mean total pixel area and percent pixel area of the overall GLUT1 
expression to our GLUT1+ macrophages subsets in among NHP. We found a lack of significant 
difference between the overall GLUT1 expression and GLUT1+ epithelioid macrophages.  
 
 
Figure 8. Macrophages contribute to, but are not the sole source, of overall granuloma GLUT1 expression 
Comparison of the A) the total pixel area and B) percent pixel area of the GLUT1 expression in each macrophage 
subset and the to the overall GLUT1 expression in lung granulomas. 
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 Flow Cytometry with GLUT1 
In order to identify the non-macrophage cell types that contribute to overall GLUT1 
expression in granulomas, we used flow cytometry to identify GLUT1+ immune cells in lung 
granulomas. We stained the homogenate for myeloid cells, CD3+ T cells and CD20+ B cells, and 
also examined the population of unclassified CD3-C20- lymphocyte sized cells. We identified 
each cell population using the gating strategy shown in Figure 9. We calculated the frequency of 
GLUT1+ cells and the GLUT1 index  of B cells, T cells, neutrophils (PMN), macrophages, and 
unclassified cells by multiplying the number of GLUT1+ cells to the GLUT1 MFI. We used this 
metric (GLUT1 index), which accounts for the total number of cells in each cell population and 
GLUT1 expressed by each cell, as a metric of that population’s overall GLUT1 signature within a 
granuloma.  
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Figure 9. Gating strategy used to isolate T cells, B cells, and myeloid cells from homogenized lung granulomas 
from macaque granulomas 
 
 
We first sought to identify the frequency of GLUT1+ cells for each of our gated cell 
populations (Figure 10 Left) where the individual granulomas are represented by the small dots 
(red, M22018; grey, M23818; blue, M23318) and the large dots represent the median frequency 
of GLUT1+ positive for each animal. We are presenting the data in this manner because although 
granulomas are analyzed as discrete units (the granuloma), an animal will have multiple 
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granulomas that all have related features that are more similar to each other than to granulomas 
from another animal. In this regard, each granuloma resembles a replicate in an experiment and 
the animals represent an independent experiment. For our analysis, we are comparing the 
individual animal (large dot) data rather than the individual granuloma (small dot) data. Using the 
Friedman test (non-parametric one-way ANOVA for paired data), we found a significant 
difference in the frequency of %GLUT1 positive epithelioid macrophages and unclassified 
lymphocyte-sized cells. 
 
Figure 10. Different cell subsets express variable amounts of GLUT1 in granulomas 
(Left) The columns represent the median frequency of GLUT1+ B cells, T cells, unclassified lymphocyte-sized cells, 
neutrophils (PMN), and macrophage subsets. * indicates p<0.05. (Right) Column graphs with bars representing the 
median overall GLUT1 expression by each cell subset after accounting for population size (GLUT1 index). Individual 
granulomas are represented by small dots and large dots represent the median of all granulomas from an animal where 
each animal is represented by a different color. 
 
To get a better sense for how much each population contributes to the overall GLUT1 
expression in a granuloma, where we are considering GLUT1 as a proxy for glycolytic 
metabolism, we calculated a GLUT1 index that accounts for the total number of cells with a 
population and the overall GLUT1 expression/cell. More so, GLUT1 index took into account 
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differences in size between cell types and difference in number of cells found in a granuloma of 
each cell type. We did not find a significant difference when comparing the median GLUT1 index 
of each NHP (Figure 10 Right). The overall GLUT1 expression per granuloma (GLUT1 index) 
when accounting for cell population size suggests that a granuloma’s overall capacity to use 
glucose is multifactorial and although macrophages may express more GLUT1 on a per cell basis, 
inflammation driven by large numbers of cells with lower GLUT1 expression can be important 
contributors to glucose uptake. 
 Modeling Glucose Uptake with 2-NBDG 
3.4.1 Macrophage 2-NBDG uptake 
Cells in different granuloma regions are exposed to variable amounts of bacterial antigen 
and hypoxia. The effect these conditions have on macrophages cannot be assessed in vivo and so 
we used in vitro experiments with monocyte-derived macrophages to model the effect of Mtb 
exposure or low oxygen conditions on glucose uptake. In order to determine if gamma-radiated 
Mtb (yMtb) can stimulate macrophages to uptake glucose, we performed four glucose uptake 
assays using a glucose analog, fluorescence-labeled 2-deoxyglucose, 2-NBDG, on monocyte-
derived macrophages from four different NHPs (M22618, M13618, M21718, and M22118). After 
taking images, we quantified the mean intensity of 2-NBDG in the cells at 10 minutes, 30 minutes, 
1 hour, 3 hour, and overnight timepoints with CellProfiler (Figure 11).  
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Figure 11. Monocyte derived macrophages take up 2-NBDG after stimulation with Mtb 
Microscopy of monocyte-derived macrophages from PBMCs of NHP infected with Mtb that were either stimulated 
or unstimulated with gamma-radiated Mtb at the 1-hour timepoint. Green fluorescence is 2-NBDG. 
 
There was a significant amount of inter-cell variability within a treatment condition 
indicating that macrophage glucose uptake is heterogenous within a culture. In Figure 12 Left, 
shows the results from one NHP (M13618) and when the control (no stimulation) and Mtb-
stimulated cells were compared with a non-parametric T test (Mann Whitney), there was a 
significant difference between unstimulated and stimulated cells with there being an increase in 2-
NBDG uptake occurring within 30 minutes.  
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Figure 12. 2-NBDG on monocyte-derived macrophages  from PBMCs of NHP infected with Mtb that were 
either stimulated or unstimulated with gamma-radiated Mtb 
(Left) a 2-NBDG uptake assy showing the fluorescence intensity at each timepoint from one NHP (M13618) 
(Right) Comparing the median 2-NBDG intensity of all four glucose uptake assays per NHP (M13618, green; 
M22618, blue; M22718, grey; M22118, black) and comparing the median 2-NBDG among all four NHP (red). 
 
We normalized the data by calculating the percent change from unstimulated control by 
dividing the median stimulated MFI by the median unstimulated MFI (Figure 13, right). We then 
calculated the median of these values for all NHP together, as shown in red (Figure 13, right).  
Overall, these data suggest that macrophages can be activated by exposure to Mtb antigen and take 
up glucose within three hours of stimulation. We also noted substantial variability between animals 
and speculate this may be attributable to different differences in the number of antigen specific-T 
cells that are present in the monocyte-derived macrophage cultures after the initial CD14 isolation.  
3.4.2 Hypoxic Experiments with 2-NBDG 
Cells shift toward glycolytic metabolism to survive in hypoxic environments, and because 
our IHC-based data suggest that GLUT1+ epithelioid macrophages exist in hypoxic environments, 
we hypothesized that macrophages in hypoxic environments would take up more glucose (2-
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NBDG) than macrophages in normoxic environments. We lack access to a hypoxia chamber that 
can accommodate BSL2+ nonhuman primate cells, and so to test this hypothesis, we incubated 
cells in a desiccator where the oxygen had been exhausted by a candle. Rather than analyze the 2-
NBDG fluorescence by microscopy, we used flow cytometry to determine if this approach was 
suitable for this assay. By using flow cytometry, we were able to identify macrophage populations 
and residual T cells that remained in culture after monocyte isolation and determined the 2-NBDG 
MFI of these cell populations (Figure 14). We can see that for both T cells and macrophages 
(myeloid gate) that there is a lack of difference between 1 hour and 3 hours in all four of our 
conditions (hypoxic with stimulation, hypoxic without stimulation, normal with stimulation, and 
normal without stimulation).  
 
Figure 13. 2-NBDG MFI of CD3+ lymphocytes and CD11b+ macrophages 
Comparisons of 2-NBDG MFI for each of our experimental conditions (hypoxic with stimulation, hypoxic without 
stimulation, normal with stimulation, and normal without stimulation) for T cells and macrophages at 1 hour and 3 
hours.  
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We were able to perform one assay with cells from one animal before being forced to end 
our experiments because of the COVID-19 pandemic; thus, these data are pilot data to demonstrate 
proof of concept that this approach can be used for this assay. Because of the limited dataset, we 
are not making interpretations of this data, but note that monocyte-derived macrophages still 
contain residual populations of lymphocytes (Figure 14) with CD3+ T cells. We found that T cells 
took up substantially less 2-NBDG than macrophages, but although there appeared to be a trend 
toward greater 2-NBDG uptake in cells incubated under hypoxia for 3 hours, we did not see an 
obvious trend that related to exposure to yMtb (Figure 15). 
 
 
 
Figure 14. 2-NBDG MFI of CD3+ lymphocytes and CD11b+ macrophages 
Comparison of CD3+ T cells and CD11b+ macrophages at 1 and 3 hours that were either stimulated or unstimulated 
with Mtb in a hypoxic or oxygenated environment. 
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4.0 Discussion 
We used GLUT1 expression as a proxy for glycolytic metabolism in granulomas as well 
as 2-NBDG with monocyte-derived macrophages to identify the relationship between Mtb antigens 
and macrophage glucose uptake, thus offering mechanistic insights into granuloma biology. My 
hypothesis was that macrophages in regions of hypoxia or with exposure to Mtb antigens will 
express more GLUT1 as compared to regions of normoxic conditions or lower Mtb exposure in 
lung granulomas. Thus, my specific aims are to 1) identify which cell types in granulomas use 
glycolysis as their energy source and 2) identify potential drivers of glycolysis in granuloma 
macrophages. 
 Epithelioid Macrophages Express GLUT1 in Lung Granulomas 
GLUT1 is a well characterized glucose transporter expressed by leukocytes that has been 
used as an indicator of immune cell glycolysis metabolism (37). We found a significantly higher 
proportion of the granuloma area was occupied by GLUT1+ macrophages than GLUT1-  
macrophages. More so, we found that GLUT1 expression varies among macrophage subsets with 
epithelioid macrophages expressing more GLUT1 as compared to interstitial and alveolar 
macrophages. Epithelioid macrophages are likely important contributors to the overall granuloma 
glucose uptake, since we saw a lack of significant difference between the overall GLUT1 
expression and epithelioid macrophages per NHP.  
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M1 and M2 macrophages differ in immunometabolic responses in the presence of Mtb 
(25). M1 macrophage polarization is characterized by an up-regulation of genes consistent with 
the Warburg effect (25). M1 macrophages are activated after stimulation with LBS or TLR ligation 
(25, 39, 40). More so, epithelioid macrophages are near the caseous region of the granuloma, these 
cells are exposed to Mtb antigen as well as in an area of low oxygen. Through these IHC 
experiments, we can see that epithelioid macrophages act more like M1 macrophages likely due 
their location within a granuloma. In order to survive in this environment, these cells likely switch 
from oxidative phosphorylation to glycolysis to generate ATP faster. 
Unlike M1 macrophages, M2 macrophages upregulates Arg-1, signal transducer and 
activator of transcription 6 (STAT6), and GATA binding protein 3 (GATA3) in order to produce 
anti-inflammatory cytokine IL-10 (25). M2 macrophages have an intact TCA cycle to allow for 
the generation of ATP through oxidative phosphorylation and concomitantly display increased 
glycolysis as a carbon source (43, 44). Since interstitial and alveolar macrophages do not express 
as much GLUT1 as compared to epithelioid, it could indicate that these macrophages are following 
more of M2 macrophage metabolism or are just not as activated in lung granulomas. More so, 
these macrophages are located toward the outer areas of the granuloma where there is less Mtb 
antigen and is more oxygenated. From previous studies conducted by Mattila et al. 2013 and from 
our IHC microscopy, we can see that interstitial and alveolar macrophages are located in the 
lymphocyte cuff and could be have more anti-inflammatory properties, like M2 macrophages.  
Since we found that there was not a significant difference between the overall GLUT1 
expression and the sum of the GLUT1+ macrophage expression (per granuloma level), this 
provides evidence that other immune cells are likely contributing to the overall GLUT1 expression 
in addition to macrophages.  
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 T cells, B cells, and Myeloid Cells Express GLUT1 in Lung Granulomas 
Enhanced utilization of glycolysis occurs in other immune cells such as dendritic cells 
(DCs), natural killer cells (NK), and T cells where it is important for rapid replication and high 
levels of activity including cytokine expression (37). To show that other cells types found in lung 
granulomas also express GLUT1, we used lung granulomas from NHP infected with Mtb and flow 
cytometry to determine the frequency of GLUT1 and the GLUT1 index of B cells, T cells, 
neutrophils (PMN), and macrophages. We found that T cells, B cells, neutrophils, and 
macrophages all express GLUT1 in lung granulomas but macrophages, T cells, and neutrophils 
(PMN) had a higher frequency of GLUT1 expression and GLUT1 index as compared to B cells 
and unclassified cells. This supports that that other immune cells in granulomas are contributing 
to the overall GLUT1 expression in lung granulomas. Macrophages are larger than T cells but 
there is a larger number of T cells within a granuloma than macrophages. Although we used the 
GLUT1 index to try to account for these differences, this could still be a reason for the lack of 
difference in GLUT1 expression between T cells and macrophages.  
The flow cytometry data supports the data seen in our IHC experiments that macrophages 
are highly express GLUT1. As well as support the notion that that along with macrophages, T 
cells, B cells, and other myeloid cells are activated in lung granulomas and contribute to the overall 
GLUT1 expression seen in lung granulomas. Overall, we see that macrophages express the most 
GLUT1 followed by T cells and neutrophils and then B cells and unclassified cells. 
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 Macrophages are ACTIVATED UPON STIMULATION with Mtb Antigen 
PET-CT using fluorodeoxyglucose (18F-FDG), a glucose analog, has become an 
increasingly important tool for diagnosing TB (48) and uncovering the drivers of glucose uptake, 
as visualized by 18F-FDG PET signal, can be translated into meaningful insight into the 
development and cellular changes that occur in granulomas. In addition to 18F-FDG, studies have 
shown that using 2-NBDG, a fluorescent analog of D-glucose, can also be used to as a probe for 
monitoring glucose uptake in malignant tumor cells (50). By using 2-NBDG, a glucose analog 
similar to FDG, we can perform experiments that could give insight to the mechanics of glycolysis 
in monocyte-derived macrophages. In our experiments using 2-NBDG, we found that monocyte-
derived macrophages are quickly activated upon stimulation with yMtb. This further indicates that 
upon infection, macrophages are quickly activated and use glycolysis to produce ATP. Although, 
we also saw that there is a high variation among NHP and requires further analyses to better 
determine the relationship between yMtb stimulation and macrophage activation.  
Data from the 2-NBDG assay and the flow cytometry data using the NHP lung granulomas 
validate the PET-CT images, in that macrophages are likely contributing to the 18F-FDG PET 
signal. This 2-NBDG data can help to better understand the diagnostic power of PET-CT, as 
macrophages quickly take up 2-NBDG upon stimulation. We can use 18F-FDG PET-CT in 
conjunction with 2-NBDG to follow disease progression and treatment outcomes.  
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 Evidence Toward Hypoxia Effecting 2-NBDG UPTAKE in Macrophages  
Glycolysis enables tumor cells to survive and replicate rapidly in normoxic and hypoxic 
environments (38). Granulomas are poorly vascularized structures that lack nutrients and oxygen, 
especially at the core of the lesion (54). Macrophages are the most abundant immune cell at the 
center of granulomas and must  adapt to this hypoxic condition, such as using glycolysis to 
generate more ATP (54). Macrophages increase hypoxia-inducible factor 1- (HIF1), which is 
directly involved in cell growth, differentiation, and survival (54). In normoxic conditions, HIF1 
has a short half-life, but under hypoxic conditions, HIF1 becomes transcriptionally active and 
the classical target genes include glucose transporters (54). HIF1 can also be stimulated by 
stimuli such as LPS, TBF, and glucose concentrations in nonhypoxic conditions (54).  
Commonly seen in malignant tumors, cells have the ability to increased cellular glycolysis 
and increase glucose uptake (50). By using glucose analogs, PET CT can be used to create images 
to identify malignant tumors (50). Although 2-doxy-2-[F-18]fluoro-D-glucose (FDG) is 
commonly used as the glucose analog for PET CT, studies have shown that another glucose analog, 
2-NBDG  can also be used as a probe for glucose uptake in malignant cells (50).  
Through our experiments using the hypoxic chamber, we saw lack of any evidence that 
stimulation or hypoxic conditions affect 2-NBDG MFI. We did find that T cells took up 
substantially less 2-NBDG than macrophages, although there appeared to be a trend toward greater 
2-NBDG uptake in cells incubated under hypoxia for 3 hours. We did not see an obvious trend that 
related to exposure to yMtb. Since this was a pilot experiment, it would be useful to repeat this 
experiment to determine if this is a normal trend. It would also be useful to include HIF1 and 
GLUT1 cell surface staining to determine if these cells are expressing these cell markers. This 
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would help conclude if glycolysis and hypoxia are related to each other in macrophages. By further 
understanding the relationship between macrophage metabolism, HIF1a, and Mtb exposure, we 
can provide new treatments that could reduce treatment lengths by disrupting metabolism of 
infected immune cells to reduce Mtb dissemination.  
 Conclusions  
Overall, by looking at each of our methods, we see evidence that macrophages and other 
cells in lung granulomas express GLUT1 and that macrophages are activated when exposed to Mtb 
antigen. We also found some evidence that macrophages are activated in hypoxic environments, 
but further experiments are warranted to make any definitive conclusions. We speculate that upon 
infection, that macrophages, such as epithelioid macrophages, are infected but not fully activated. 
Once T cells are primed and return, they activate these macrophages. These macrophages then 
switch to glycolysis, produce chemokine and cytokines to activate other immune cells, and  the 
granuloma forms (3-4 weeks post infection). Around this same time, we are able to use PET-CT 
to identify these lung granulomas due to macrophages and other immune cells using glycolysis as 
their energy source and able to take in FDG.    
My hypothesis was that macrophages in regions of hypoxia or with exposure to Mtb 
antigens will express more GLUT1 as compared to regions of normoxic conditions or lower Mtb 
exposure in lung granulomas. Thus, my specific aims were to 1) identify which cell types in 
granulomas use glycolysis as their energy source and 2) identify potential drivers of glycolysis in 
granuloma macrophages. Through this study, we were able to show evidence of GLUT1 
expression, a proxy for glycolysis, in macrophages, T cells, and neutrophils (PMNs) as well as 
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how that Mtb antigen can activate macrophages. We were able to further understand 
immunometabolism in granulomas and support my hypothesis through my specific aims.  
 Public Health Statement 
Since we know that macrophages are likely contributors to FDG signal, we can further 
develop the use of PET-CT with 2-NBDG to help with diagnostics and treatment outcomes. More 
so, it can give us the ability to better study granuloma formation and disease progression. By 
understanding immunometabolism in granulomas, we can create therapeutics to help combat Mtb 
infection or reduce duration of treatment to avoid multidrug resistance by directly disrupting 
infected immune cells metabolism. 
 Future Directions 
Future directions would conduct experiments to understand the metabolism of Mtb and its 
interaction with the host. More so, granulomas can be formed in other tissues, such as lymph nodes, 
and would be important to determine if immunometabolism of immune cells in other tissues are 
similar to the lung. And lastly, further evidence is needed to determine if bacterial burden (CFU) 
can relate to GLUT1 expression and immunometabolism in granulomas.  
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Appendix A ImadeJ Macro for Image Analysis 
Below is the macro used for image analysis on the lung tissue granulomas to determine the 
total area and percent area in pixels of GLUT1, CD11c, CD163 individually and in colocalization 
with one another.  
//Create an ROI. Measure area of red, green, blue stain. Measure area of colocalization of 
stains, with stain not of interest subtrated out (eg. red AND green NOT blue). Count total cells. 
Count cells that are red AND not green or blue. 
 
//area and % area of red 
//area  and % area of green 
//area  and % area of blue 
//area  and % area of red without colocalized green and blue 
//area  and % area of red + green colocalization without blue 
//area  and % area of red + blue colocalization without green 
//area  and % area of red + green + blue colocalization 
//area  and % area of blue without colocalized green and red 
//area  and % area of red without colocalized red and blue 
//area  and % area of blue + green colocalization without red 
//Cell Count using DAPI (cells that are red without colocalized green and blue) 
 
//THIS MACRO ONLY COUNTS THE NUMBER OF CELLS USING THE DAPI 
IMAGE. IGNORE THE COUNTS COLUMN IN THE SUMMARY WINDOW FOR 
ANYTHING LABELED AS 'AREA OF'. 
 
 
waitForUser("JUST A REMINDER THAT THIS MACRO ONLY COUNTS THE 
NUMBER OF CELLS USING THE DAPI IMAGE. IGNORE THE COUNTS COLUMN IN THE 
SUMMARY WINDOW FOR ANYTHING LABELED AS 'AREA OF'. Click OK to continue"); 
 
waitForUser("Open DAPI Image. Wait for image to open and then click OK") 
waitForUser("Draw ROI, click Ctrl + t, then click OK"); create region of interest and add 
that region to the ROI manager. 
run("Clear Outside"); remove any part of the DAPI image that is not contained within the 
ROI. 
rename("DAPI") rename the current image 
 
waitForUser("Open RGB Image. Wait for image to open and then click OK") 
roiManager("Select", 0); select the first ROI in the ROI manager and apply to the RGB 
image 
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setBackgroundColor(0, 0, 0); [I’m guessing this is to choose the color black] 
run("Clear Outside"); remove any part of the RGB image that is not contained within the 
ROI. 
 
 
waitForUser("Click More on ROI Manager window and save the ROI as an overlay,then 
click OK") 
 
currentTitle = getTitle(); retrieve the file name 
run("Split Channels"); split the  RGB image into red, green, and blue individual images 
greenTitle = currentTitle + " (green)"; name green image with file name and green 
redTitle = currentTitle + " (red)"; name red image with file name and red 
blueTitle = currentTitle + " (blue)"; name blue image with file name and blue 
 
 
selectWindow(redTitle); select red image 
run("Duplicate...", "redTitle") duplicate the red image so that the original image can be 
used twice in this macro 
rename(redTitle + " area of red") rename duplicate image with file name and area of red 
setAutoThreshold("Default"); open threshold with default settings 
run("Threshold..."); a threshold range is set to tell the objects of interest apart from the 
background 
waitForUser("Set the threshold by using the slider (DO NOT click Apply) then click OK"); 
allow user to set the threshold manually 
setOption("BlackBackground", false); apply the threshold to the image 
run("Convert to Mask"); converts the image to black and white based on the current 
threshold settings; this is now an 8-bit image 
run("Close"); close the threshold window 
run("Invert"); pixels that are currently displayed as white will become black, and vice versa 
roiManager("Select", 0); select the first ROI in the ROI manager and apply to the current 
image 
run("Analyze Particles...", "size=0-Infinity show=Overlay display summarize in_situ"); 
select the particles that are sized between zero and infinity; for the particles that are selected draw 
a line around them; display data in the results table; put the info for the particles into the summary 
table; open the resulting image with the overlay in a new window 
run("Invert"); pixels that are currently displayed as white will become black, and vice versa 
run("RGB Color"); this will change the image from an 8-bit image to an RGB image 
 
selectWindow(greenTitle); 
run("Duplicate...", "greenTitle") 
rename(greenTitle + " area of green") 
setAutoThreshold("Default"); 
run("Threshold..."); 
waitForUser("Set the threshold by using the slider (DO NOT click Apply) then click OK"); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
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run("Invert"); 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity show=Overlay display summarize in_situ"); 
run("Invert"); 
run("RGB Color"); 
 
selectWindow(blueTitle); 
run("Duplicate...", "blueTitle") 
rename(blueTitle + " area of blue") 
setAutoThreshold("Default"); 
run("Threshold..."); 
waitForUser("Set the threshold by using the slider (DO NOT click Apply) then click OK"); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
run("Close"); 
run("Invert"); 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity show=Overlay display summarize in_situ"); 
run("Invert"); 
run("RGB Color"); 
 
imageCalculator("Subtract create", redTitle + " area of red", greenTitle + " area of green"); 
remove any area of the image that is in both the images and create a new image 
rename("area of red - area of green") 
imageCalculator("Subtract create", "area of red - area of green", blueTitle + " area of 
blue"); 
run("8-bit"); change the image to an 8-bit image 
run("Invert"); 
rename(redTitle + " area of red without colocalized green and blue") 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity   show=Overlay display summarize in_situ"); 
run("Invert"); 
run("RGB Color"); 
 
 
imageCalculator("AND create", redTitle + " area of red", greenTitle + " area of green"); 
keep only the parts of the two images that overlap and create a new image 
rename("area of red + area of green") 
imageCalculator("Subtract create", "area of red + area of green", blueTitle + " area of 
blue"); 
run("8-bit"); 
run("Invert"); 
rename(redTitle + " area of red + green colocalization without blue") 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity   show=Overlay display summarize in_situ"); 
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imageCalculator("AND create", redTitle + " area of red", blueTitle + " area of blue"); 
rename("area of red + area of blue") 
imageCalculator("Subtract create", "area of red + area of blue", greenTitle + " area of 
green"); 
run("8-bit"); 
run("Invert"); 
rename(redTitle + " area of red + blue colocalization without green") 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity   show=Overlay display summarize in_situ"); 
 
 
imageCalculator("AND create", "area of red + area of blue", greenTitle + " area of green"); 
run("8-bit"); 
run("Invert"); 
rename(redTitle + " area of red + green + blue colocalization") 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity   show=Overlay display summarize in_situ"); 
 
imageCalculator("Subtract create", blueTitle + " area of blue", greenTitle + " area of 
green"); 
rename("area of blue - area of green") 
imageCalculator("Subtract create", "area of blue - area of green", redTitle + " area of red"); 
run("8-bit"); 
run("Invert"); 
rename(blueTitle + " area of blue without colocalized green and red") 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity   show=Overlay display summarize in_situ"); 
 
imageCalculator("Subtract create", greenTitle + " area of green", redTitle + " area of red"); 
rename("area of green - area of red") 
imageCalculator("Subtract create", "area of green - area of red", blueTitle + " area of 
blue"); 
run("8-bit"); 
run("Invert"); 
rename(greenTitle + " area of green without colocalized red and blue") 
roiManager("Select", 0); 
run("Analyze Particles...", "size=0-Infinity   show=Overlay display summarize in_situ"); 
 
imageCalculator("AND create", blueTitle + " area of blue", greenTitle + " area of green"); 
rename("area of blue + area of green") 
imageCalculator("Subtract create", "area of blue + area of green", redTitle + " area of red"); 
run("8-bit"); 
run("Invert"); 
rename(blueTitle + " area of blue + green colocalization without red") 
roiManager("Select", 0); 
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run("Analyze Particles...", "size=0-Infinity   show=Overlay display summarize in_situ"); 
 
selectWindow("DAPI"); 
rename("Cell Count using DAPI") 
run("8-bit"); 
setAutoThreshold("Default"); 
run("Threshold..."); 
waitForUser("Set the threshold (DO NOT click Apply), then click OK");  
run("Close");  
setOption("BlackBackground", false); 
run("Convert to Mask"); 
run("Invert"); 
run("Watershed"); used to segment objects 
roiManager("Select", 0); 
run("Analyze Particles...", "size=10-infinity show=Overlay display summarize add 
in_situ"); the “add” in this step will add each particle to the ROI Manager as an individual ROI 
run("Fill Holes") fill in any “holes” that are in objects to make them solid 
run("Watershed"); 
run("Invert"); 
run("RGB Color"); 
 
roiManager("Select", 0); 
roiManager("Delete"); delete the first ROI, the one that was created at the beginning of this 
macro 
close("Results") close the results window so the new data will not get added onto the end 
of the previous data 
 
imageCalculator("AND create", "Cell Count using DAPI", redTitle + " area of red without 
colocalized green and blue"); 
rename(redTitle + " Cell Count of red without green and blue colocalization, using DAPI") 
close("Results") 
run("8-bit"); 
setAutoThreshold("Default"); 
run("Threshold..."); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
run("Invert"); 
 
roiManager("Show All"); this is just so the ROI Manager window is selected 
roiManager("Measure"); measure and record the data for each individual ROI that was 
created in the above analyze particle step (from the DAPI image) 
 
waitForUser("Copy Summary and Results and paste into Excel. Sort the Results and count 
# of objects that are not zero or 255, that is your # of cells that are also red (without colocalized 
green and blue). When ready to close all, click OK"); 
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The rest of these steps will just close all of the open windows. 
selectWindow("ROI Manager"); 
run("Close"); 
selectWindow("Threshold"); 
run("Close"); 
 
close("Results") 
close("Log") 
run("Close All"); 
close("Summary") 
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Appendix B NBDG Chemical Formulation 
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